TABLE 2.
Year | Author | Size (N) | Follow‐up (months) | Statin Type | Severity of Disease | Results (HR, 95% CI) | |
---|---|---|---|---|---|---|---|
Prospective | 2019 | Jouve et al. 56 | 323 | 35 | Pravastatin | Cirrhosis | No benefit versus sorafenib |
2020 | Tran et al. 70 | 475,768 | 55 | Mixed* | Mixed | HCC reduction (0.61, 0.43‐0.87) | |
Retrospective | 2005 | Friis et al. 71 | 348,262 | 40 | Mixed | No cirrhosis | Reduced cancer, HCC (0.86, 0.78‐0.95) |
2008 | Friedman et al. 72 | 361,859 | 113 | Mixed (75% lovastatin) | No cirrhosis | HCC reduction favored to be confounding | |
2009 | El‐Serag et al. 50 | 6518 | 29 | Mixed | Mixed | HCC reduction (0.74, 0.64‐0.87) | |
2011 | Chiu et al. 73 | 2332 | 48 | Mixed (46% ATV) | Mixed | HCC reduction (0.62, 0.42‐0.91) | |
2011 | Marelli et al. 74 | 91,714 | 55 | Mixed | No cirrhosis | No change in total cancer risk | |
2012 | Tsan et al. 75 | 33,411 | 12 | Mixed | Mixed | Dose‐dependent HCC reduction (0.53, 0.49‐0.58) | |
2013 | Tsan et al. 76 | 260,864 | 12 | Mixed (47% ATV) | Mixed | Dose‐dependent HCC reduction (0.47, 0.36‐0.61) | |
2014 | McGlynn et al. 77 | 562 | 132 | Mixed | Mixed | HCC reduction (0.32, 0.15‐0.67) | |
2014 | Björkhem‐Bergman et al. 78 | 105,715 | 54 | Mixed (86% SMV) | No cirrhosis | HCC reduction (0.88, 0.81‐0.96) | |
2015 | Chen et al. 79 | 71,847 | 108 | Mixed | Mixed | HCC reduction (0.28, 0.23‐0.35) | |
2015 | Hsiang et al. 67 | 73,499 | 24 | Mixed (85% SMV, ATV) | No cirrhosis | HCC reduction (0.68, 0.48–0.97) | |
2016 | Simon et al. 39 | 9135 | 168 | ATV, fluvastatin | Mixed | Dose‐dependent HCC reduction (0.60, 0.07‐0.90) | |
2017 | Kawaguchi et al. 53 | 734 | 132 | Mixed | Mixed | Reduced HCC recurrence (0.34, P = 0.005) | |
2017 | Kim et al. 51 | 1374 | 144 | Mixed | Mixed | HCC reduction (0.36, 0.22‐0.60) | |
2018 | Kim et al. 80 | 9852 | 144 | Mixed (67% SMV, ATV) | Mixed | HCC reduction (0.44, 0.33‐0.58) | |
2019 | Menon and Mathew 81 | 12,861 | 288 | Mixed | Mixed | HCC reduction (0.993, 0.992‐0.994) | |
2019 | Cho et al. 54 | 347 | 60 | Mixed | No cirrhosis | Reduced HCC recurrence (0.32, 0.11‐0.89) | |
2019 | Simon et al. 57 | 63,279 | 120 | Lipophilic | Mixed | HCC reduction (0.56, 0.41‐0.79) | |
2020 | Goh et al. 82 | 7713 | 60 | Mixed | Mixed | HCC reduction (0.36, 0.19‐0.68) | |
2020 | German et al. 52 | 102 | 168 | Mixed | Cirrhosis | HCC reduction (0.20, 0.07‐0.60) |
Mixed refers to no cirrhosis and cirrhosis.